Study Stopped
study was never initiated, No participants enrolled
Pediatric Atopic Dermatitis (AD) Internet Survey
Using an Internet Survey to Improve Adherence in Pediatric Atopic Dermatitis
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jun 2011
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2011
CompletedFirst Submitted
Initial submission to the registry
June 28, 2011
CompletedFirst Posted
Study publicly available on registry
June 30, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 27, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
October 27, 2014
CompletedJuly 6, 2018
July 1, 2018
3.4 years
June 28, 2011
July 3, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Adherence to topical triamcinolone
12 weeks
Secondary Outcomes (2)
Eczema Area Severity Index
12 weeks
Investigator's Global Assessment
12 weeks
Study Arms (2)
Weekly Internet survey w medication
EXPERIMENTALWeekly survey via email plus topical triamcinolone
Topical triamcinolone only
ACTIVE COMPARATORStandard of care
Interventions
Parents will complete a weekly online survey about medication use.
Topical triamcinolone to all affected areas once daily
Eligibility Criteria
You may qualify if:
- Any child age 2 to 8 with a diagnosis of atopic dermatitis confirmed by a dermatologist, together with the child's parent/guardian. Written consent must be given by parent/guardian.
You may not qualify if:
- Child is less than 2 or greater than 8 years of age.
- Known allergy or sensitivity to topical triamcinolone in the child.
- Inability to complete all study-related visits, or inability to complete the Internet survey due to inadequate Internet access.
- Introduction of any other prescription medication, topical or systemic, for atopic dermatitis while participating in the study. Subjects who are on systemic anti-inflammatory treatments for atopic dermatitis must be on a stable dose for at least 3 months prior to enrollment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Steven R Feldman, MD, PhD
Wake Forest University Health Sciences
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 28, 2011
First Posted
June 30, 2011
Study Start
June 1, 2011
Primary Completion
October 27, 2014
Study Completion
October 27, 2014
Last Updated
July 6, 2018
Record last verified: 2018-07
Data Sharing
- IPD Sharing
- Will not share